Aspira Women’s Health (NASDAQ:AWH) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the stock.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $3.30 price objective on shares of Aspira Women’s Health in a report on Wednesday, April 10th.

Aspira Women’s Health Stock Performance

NASDAQ:AWH opened at $2.54 on Tuesday. Aspira Women’s Health has a fifty-two week low of $2.17 and a fifty-two week high of $6.75. The business has a 50 day moving average price of $3.22 and a 200-day moving average price of $3.74. The firm has a market cap of $31.62 million, a PE ratio of -1.75 and a beta of 1.57.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Wednesday, May 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). The business had revenue of $2.15 million during the quarter, compared to the consensus estimate of $2.10 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 163.95%. During the same period in the previous year, the business earned ($10.94) earnings per share. Research analysts predict that Aspira Women’s Health will post -1.3 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Northeast Financial Consultants Inc bought a new position in Aspira Women’s Health in the 3rd quarter worth $126,000. B. Riley Wealth Advisors Inc. lifted its position in shares of Aspira Women’s Health by 39.0% in the third quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock valued at $672,000 after acquiring an additional 35,177 shares in the last quarter. Finally, Quantum Private Wealth LLC boosted its stake in shares of Aspira Women’s Health by 76.8% in the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after acquiring an additional 21,788 shares during the period. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.